Dr. Michael W. Schuster, MD

Medicare patients and services

Medicare patients, 2024

276

Services billed

1,275

Patients’ average age

74

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 24 companies reported 125 payments worth $120,496 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $1,029,265 in research payments for these studies, mostly to the institutions running them.

• A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
  Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05730036
• A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05828511
• A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
  Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06140524
• A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
  Incyte Corporation
• A Study to Evaluate the Efficacy and Safety of Lisocabtagene Maraleucel Monotherapy Compared to Investigators Choice Options (Idelalisib + Rituximab or Bendamustine + Rituximab) in Adult Participants with Double Class…
  Celgene Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in New York

• Mohammad Maher Abdul Hay, MD
• Wassim Abida, MD, PHD
• Ghaith F. Abu Zeinah, M.D.
• Sylvia Adams, MD
• Amit B. Agarwal, M.D.
• Meena Ahluwalia, M.D
• Katya Ahr, MD
• Mohammad Alhomoud